Table 4.
Treatment success at 96 h (primary outcome) and use of topical antibiotic therapy according to treatment arm (n =8 4 neonates).
| Euphrasia (n = 42 neonates) | Missing data | Placebo (n = 42 neonates) | Missing data | p-valuea | |
|---|---|---|---|---|---|
| Success of treatment at 96 h | 22 (55.0%) | 2 | 21 (51.2%) | 1 | 0.85 |
| Topical antibiotic therapy | 8 (19.0%) | - | 8 (19.0%) | - | 0.99 |
| Time to initiation of antibiotic therapyb | - | - | 0.99 | ||
| Within 48 h | 5 (62.5%) | 4 (50.0%) | |||
| Between 48 and 96 h | 3 (37.5%) | 4 (50.0%) | |||
| Decreasing of symptoms after topical antibiotic therapy | 6 (75.0%) | - | 6 (75.0%) | - | 0.99 |
Data are expressed as number (percentage).
Treatment success was defined as no ocular discharge at 96 h and no use of topical antibiotic therapy during the 96-h intervention period. If a neonate presented a bilateral affection, the treatment was defined as successful only if ocular discharge had disappeared in both eyes at 96 h.
a
Chi-square test or Fischer test, as appropriate.
b
In the 8 neonates who received a topical antibiotic therapy.